# PEG-MGF: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on PEG-MGF — the pegylated Mechano Growth Factor E-peptide marketed for muscle repair and recovery. Preclinical-only evidence, no human trials, and a restricted 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
PEG-MGF is a clever pharmacokinetic fix — pegylation rescues the otherwise unusable minutes-long half-life of the Mechano Growth Factor E-peptide so it can in principle be given systemically — wrapped around a *biology that is still unproven in humans and partly contradicted in the primary literature*. Its highest evidence grade is **C (preclinical only)**, with marketed physique claims at Grade D. It is not FDA-approved, not authorized for compounding in 2026, and prohibited in sport at all times under WADA.[4](https://peptidevox.com/#r4)[13](https://peptidevox.com/#r13)

PEG-MGF ("Mechano Growth Factor, Pegylated") is a synthetic, polyethylene-glycol-conjugated version of the unique 24-amino-acid C-terminal E-peptide of Mechano Growth Factor, the IGF-1Ec splice variant of insulin-like growth factor-1.[1](https://peptidevox.com/#r1) It is marketed in fitness circles as a systemic muscle-repair and recovery agent. Its popularity rests almost entirely on a satellite-cell story drawn from cell-culture and rodent work; its proof in humans does not exist. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. PEG-MGF is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the unregulated literature for completeness — not as recommendations. Growth factors carry a real theoretical oncologic risk. Consult a licensed clinician before any health decision.*

## What is PEG-MGF and how does it work?

The IGF-1 gene generates several mRNA isoforms by alternative splicing; their mature IGF-1 domain is identical but their C-terminal "E-peptide" extensions differ.[1](https://peptidevox.com/#r1) MGF is the IGF-1Ec isoform in humans (IGF-1Eb in rodents), discovered in Geoffrey Goldspink's laboratory at University College London as a mechanically and injury-induced, locally expressed muscle isoform distinct from liver-derived systemic IGF-1Ea.[4](https://peptidevox.com/#r4) The pharmacologically interesting fragment is the unique 24-amino-acid C-terminal E-domain peptide, reported as the sequence YQPPSTNKNTKSQRRKGSTFEEHK, cleaved from the mature IGF-1 protein.[2](https://peptidevox.com/#r2) "MGF" as a therapeutic peptide refers to this synthetic E-domain fragment, not the full IGF-1 protein; PEG-MGF is that fragment with PEG chains covalently attached.

The proposed mechanism — all of it preclinical — is a "two-signal" model from the Goldspink group: after mechanical load or injury, the IGF-1 gene first splices toward MGF for an early proliferative/repair phase (roughly the first 24 hours), then shifts to IGF-1Ea for a differentiation/hypertrophy phase.[4](https://peptidevox.com/#r4) In cell culture the synthetic E-peptide increased myoblast proliferation while inhibiting terminal differentiation and myotube fusion, and the effect was not blocked by an antibody to the IGF-1 receptor — suggesting an IGF-1R-independent, still-unidentified receptor mechanism.[2](https://peptidevox.com/#r2) The functional claim is therefore satellite-cell activation: recruiting quiescent muscle stem cells into the cell cycle to expand the regenerative pool. Importantly, this mechanism is contested, not settled — see the evidence section.

Pegylation is the key engineering step. Native MGF E-peptide has an extremely short plasma half-life, commonly cited at about five to seven minutes, reflecting rapid proteolysis and renal clearance, which makes systemic dosing impractical.[1](https://peptidevox.com/#r1) Covalent attachment of polyethylene glycol extends half-life two ways: it greatly increases the conjugate's hydrodynamic radius, reducing glomerular filtration, and provides steric shielding against proteases. As a large, charged peptide conjugate it is not orally bioavailable, and the described route is subcutaneous injection.[15](https://peptidevox.com/#r15)

## What is the evidence by indication?

The bottom line up front: there are no human randomized controlled trials and no published human trials of any kind for MGF or PEG-MGF. Every indication below is preclinical (Grade C) or marketing/anecdotal (Grade D), and the marquee muscle claim is internally contradicted.

  PEG-MGF / MGF evidence by indication

    IndicationBest evidenceGrade

    Skeletal-muscle repair, hypertrophy & recovery (marketed use)Cell-culture myoblast proliferation + rodent overexpression; contradicted by a later primary studyC (preclinical); D for physique claims
    Cardioprotection / myocardial repairRodent myocardial-infarction models; US patent on MGF to prevent myocardial damageC (preclinical)
    NeuroprotectionRodent/gerbil brain-ischemia models; neurite outgrowth in vitroC (preclinical)
    Anti-aging / sarcopenia / "tissue regeneration"Extrapolation from the regeneration hypothesis and vendor marketingD

The muscle evidence is the most cited and the most extrapolated. In C2C12 and human myogenic cell cultures the synthetic MGF E-peptide increased myoblast proliferation and desmin expression and delayed myotube fusion via an IGF-1R-independent route, and transgenic rodent work reported a more potent hypertrophic effect than IGF-1Ea, plus modulation of inflammatory cytokines and macrophage resolution in a mouse muscle-injury model.[2](https://peptidevox.com/#r2)[5](https://peptidevox.com/#r5) But the story is not clean: a careful later primary study by Fornaro and colleagues found the synthetic MGF C-terminal peptide had no apparent effect on myoblasts or primary muscle stem cells, directly challenging the proliferation claim, and an *Endocrinology* minireview judged the in-vivo case that MGF is a distinct gene product with a role not fulfilled by full-length IGF-I to be inadequate.[3](https://peptidevox.com/#r3)[4](https://peptidevox.com/#r4) The leap from "satellite-cell activation in a dish" to "systemic muscle recovery in athletes" is unsupported by any clinical trial.

The cardiac and neural signals are genuine but equally preclinical. MGF E-peptide reduced cardiomyocyte apoptosis and improved cardiac function in rodent myocardial-infarction models, a concept captured in a US patent on using the MGF splice variant to prevent myocardial damage, and it reduced neuronal death in rodent and gerbil brain-ischemia models while promoting neurite outgrowth in vitro — again via non-IGF-1R mechanisms.[8](https://peptidevox.com/#r8)[4](https://peptidevox.com/#r4) There are no human cardiac or neurologic trials.

Proven vs hyped
Proven in humans: nothing. Hyped: the systemic muscle-recovery and physique promise, which extrapolates from cell-culture findings that a later primary study failed to reproduce. PEG-MGF remains an experimental, preclinical-stage compound whose central mechanism is contested.[3](https://peptidevox.com/#r3)

## What doses appear in the literature, and how safe is it?

Dosing is reported strictly as information, not a protocol. No human pharmacokinetic study, dose-finding trial, or pharmacopeial monograph exists, so every figure comes from non-peer-reviewed vendor and community write-ups.[15](https://peptidevox.com/#r15) Those sources commonly cite roughly 100 to 400 micrograms per subcutaneous administration, two to three times per week, on the rationale that the extended half-life maintains exposure without daily dosing.[15](https://peptidevox.com/#r15) Product is described as a lyophilized powder reconstituted with bacteriostatic water and refrigerated after mixing. Reported half-life figures range wildly from tens of minutes to two or three days across the literature, which means even the dosing-frequency rationale is unverified.

Safety data are essentially limited to mechanistic reasoning plus the general risks of unregulated injectables; there are no human safety trials. Injection-site reactions are the most commonly described practical effect.[15](https://peptidevox.com/#r15) The central theoretical concern is oncologic: as an IGF-1-pathway growth factor, MGF carries plausible cancer-promotion risk, and the IGF-1 axis has an experimentally established permissive role in carcinogenesis.[7](https://peptidevox.com/#r7) Specific to MGF, cytoplasmic IGF-1Ec was found in roughly half of analyzed lung-cancer cases, and applying MGF E-peptide to MG63 osteosarcoma cells increased proliferation, cell-cycle progression and migration with elevated cyclin D1, CD147, MMP-9 and VEGF and suppressed caspase-3 — a pro-tumorigenic, pro-angiogenic, anti-apoptotic signature.[6](https://peptidevox.com/#r6) Repeated dosing of pegylated agents can also induce anti-PEG antibodies, causing accelerated blood clearance or hypersensitivity. And because PEG-MGF is sold only as a research chemical, there is no assurance of identity, purity, correct pegylation, endotoxin control or sterility — by mechanism, anyone with active or prior malignancy, and pregnancy, lactation and pediatric populations, should be regarded as off-limits.

## What is the FDA and WADA status in 2026?

PEG-MGF is not approved for any indication and has no FDA-recognized labeling.[9](https://peptidevox.com/#r9) In September 2023 the FDA placed over a dozen peptides, including MGF/PEG-MGF, into 503A Category 2 — substances flagged as raising significant safety concerns, effectively barring compounding.[9](https://peptidevox.com/#r9) In April 2026 the FDA updated the list and removed a batch of peptides from Category 2, with Mechano Growth Factor, Pegylated among those slated for review; but removal from Category 2 is not authorization to compound — it merely lifts the explicit safety-risk designation and does not place the substance on the authorized Category 1 bulks list.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11) PEG-MGF sits in the second, later PCAC batch (alongside GHK-Cu, Melanotan II, LL-37 and Dihexa) expected to be reviewed by roughly February 2027, and even a favorable recommendation would require notice-and-comment rulemaking that can take well over a year. The net 2026 status is that PEG-MGF cannot be legally compounded under 503A or 503B and is expected to remain restricted.[10](https://peptidevox.com/#r10)

For athletes the picture is unambiguous. Mechano Growth Factors are explicitly named under WADA category S2.3, Growth Factors and Growth Factor Modulators, alongside IGF-1 and its analogues, in the [WADA Prohibited List](https://www.wada-ama.org/en/prohibited-list) in force in 2026 — prohibited at all times, in and out of competition, with no realistic Therapeutic Use Exemption.[13](https://peptidevox.com/#r13)[14](https://peptidevox.com/#r14) These are non-specified substances carrying the strictest sanctions.[12](https://peptidevox.com/#r12) Any WADA-tested athlete should treat PEG-MGF as banned regardless of its shifting FDA compounding status.

**Bottom line.** PEG-MGF pairs a genuinely clever PK fix with a biology that is unproven in humans and partly contradicted in the primary literature. The satellite-cell and cardiac/neural signals are real but entirely preclinical (Grade C); a careful primary study found no effect on muscle stem cells, and the marketed physique promise is Grade D. Against that empty efficacy ledger sit concrete concerns: a growth factor with demonstrated pro-proliferative, pro-angiogenic, anti-apoptotic activity in cancer cell lines, anti-PEG immunogenicity, and gray-market purity hazards. It is not FDA-approved, not authorized for compounding in 2026, deferred to a roughly February 2027 PCAC review, and banned at all times in sport. Regulatory facts here are current as of June 2026 and should be re-verified after the PCAC cycle.

---
Source: https://peptidevox.com/peptide-encyclopedia/peg-mgf
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt